SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

About this update from Scynexis, Inc.

[{"type":"text","content":"JERSEY CITY, N.J., Oct. 24, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced an amendment to the protocol for the ongoing FURI study investigating the safety and efficacy of oral ibrexafungerp (formerly SCY-078) as a salvage treatment for patients with resistant or refractory severe fungal infections. Ibrexafungerp, the first representative of a novel triterpenoid antifungal family being developed for oral and intravenous (IV) usage, is in clinical development for the treatment of multiple serious fungal infections, including many that have shown resistance to existing therapies. \nKey amendments to the FURI study protocol include the following:\nUnder the amended study design, patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and infections caused by other emerging fungi including yeasts and molds are now eligible for enrollment along with those suffering from Candida infections. Maximum allowed treatment duration with ibrexafungerp has been extended from 90 days to up to 180 days, as needed for chronic conditions. Ibrexafungerp will also be available as a combination therapy with standard of care (SoC) for selected subjects.\"The positive data overserved to date provide a valid rationale for expanding the use of oral ibrexafungerp to a broader set of patients with resistant, refractory and other difficult-to-treat fungal infections,\" said Dr. David Angulo, Chief Medical Officer of SCYNEXIS. \"We are thrilled to provide physicians with the option to treat a wider range of fungal infections and the ability to administer ibrexafungerp for longer durations, which is crucial to fight certain conditions with very limited treatment options. We also believe the expansion of the FURI study increases the number of targets for potential regulatory submissions under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). We continue to be encouraged by the level of interest and enrollment seen to date in our FURI study and plan to report on a second interim analysis of the data by an independent Data Review Committee in the first quarter of 2020.\"\nAbout the FURI Study\nThe FURI study is a multicenter, open label, non-comparator, single arm study to eva...

More updates from Scynexis, Inc.